ReviewCurrent issues in molecular biology2026
The Influence of Sunscreen Use on Skin Pigmentation Disorders: Melasma, Post-Inflammatory Hyperpigmentation, and Vitiligo.
Review in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Skin pigmentation is influenced by multiple factors, with sun exposure being one of the most important. Therefore, sun protection plays a central role in the prevention and treatment of pigmentation disorders. This work analysed the recent literature (2015-2025) on the influence of sun protection in melasma, post-inflammatory hyperpigmentation, and vitiligo, highlighting therapeutic advances and the impact of sunscreen use in both the prevention and treatment of these conditions. A search was conducted in the PubMed and SCOPUS databases using MeSH terms, selecting original research studies in English and employing various methodologies. Conventional sun protection (UVB/UVA) may not be sufficient on its own to prevent skin pigmentation disorders, given the evidence supporting a role for UVA1 radiation and blue light (380-455 nm) in inducing hyperpigmentation, especially in individuals with phototypes IV-VI. Innovative, broad-spectrum sunscreens, e.g., iron oxide and methoxypropylaminocyclohexenylidene ethoxyethylcyanoacetate, have shown potential for enhancing protection against hyperpigmentation in visible light, while some tinted formulations may also provide cosmetic benefits by camouflaging existing dark spots. The discrepancy between the application doses used compromises observed efficacy, reinforcing the need for public education on photoprotection and for research conducted under real-use conditions. Personalised strategies that combine broad-spectrum and visible-light protection with antioxidant and anti-inflammatory agents may optimise the prevention and management of these disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.